Clinical characteristics, follow-up, and outcomes of EXT1/EXT2-positive and EXT1/EXT2-negative LMN without proliferative features (pure class 5)
| Variable | EXT1/EXT2-Positive LMN, n=48/64 (75.0%) | EXT1/EXT2-Negative LMN, n=65/96 (67.7%) | P Valuea |
|---|---|---|---|
| Age at presentation, median (IQR), yr | 33 (25–42) | 40 (28–47) | 0.12 |
| Female, n (%) | 42 (87.5) | 53 (81.5) | 0.39 |
| SCr at presentation, median (IQR), mg/dl | 0.70 (0.60–0.90), n=46 | 0.80 (0.60–1.30), n=58 | 0.01 |
| Proteinuria at presentation, median (IQR), g/24 h | 3.5 (1.5–5.9), n=40 | 2.8 (1.40–4.3), n=51 | 0.23 |
| Proteinuria at presentation ≥3.5/d, n (%) | 23 (57.5), n=40 | 18 (35.3), n=51 | 0.04 |
| Hematuria, n (%) | 15 (31.3) | 22 (33.8) | 0.77 |
| Other autoimmune diseases, n (%) | 14 (29.2) | 15 (23.1) | 0.46 |
| Sclerosed glomeruli, median (IQR), % | 0.0 (0.0–8.5) | 9.5 (0.0–24.4) | <0.001 |
| IFTA, median (IQR), % | 0.0 (0.0–0.0) | 10.0 (5.0–25.0) | <0.001 |
| SCr at end of follow-up, median (IQR), mg/dl | 0.85 (0.70–1.13), n=38 | 1.00 (0.70–1.57), n=51 | 0.09 |
| Proteinuria at end of follow-up, median (IQR), g/24 h | 0.95 (0.20–2.55), n=26 | 0.90 (0.20–1.93), n=42 | 0.46 |
| Proteinuria at end of follow-up ≥3.5/d, n (%) | 3 (11.5), n=26 | 6 (14.3), n=42 | 0.75 |
| ESKD, n (%) | 2 (4.2) | 11 (16.9) | 0.04 |
| Death, n (%) | 2 (4.2) | 2 (3.1) | 0.76 |
| Time of follow-up, median (IQR), mo | 52.5 (31.6–81.2) | 53.6 (34.2–97.1) | 0.61 |
↵a P<0.05 is considered significant.